November 2004

Jane S. Ricciuti, RPh, MS

November 29, 2004

Introduction

The US Food and Drug Administration (FDA) approved 2 very different and new hormonal agentsLuveris (lutropin alfa) and Vantas (histrelin) Implant.

Lutropin alfa is approved for use in follicular stimulation in infertile hypogonadotropic hypogonadal women. Histrelin implant is approved for the palliative treatment of advanced prostate cancer.

This month's column reviews FDA new product approvals and labeling changes for:

Central Nervous System Agents

Imitrex (sumatriptan) Nasal Spray

Hormones

Luveris (lutropin alfa) Subcutaneous Injection
Norditropin (somatropin) Injection
Saizen (somatropin) Injection
Vantas (histrelin) Implant

1 2 3

Next Section

Cite this: November 2004 - Medscape - Nov 23, 2004.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

November 2004

Introduction

Tables

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback